We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

U.s. Commercialization Agreement Sample Contracts

between
u.s. Commercialization Agreement • March 12th, 2004 • Genta Inc De/ • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2

Standard Contracts

Free NDA TemplateoneNDA-badgeFree SaaS TemplateoneSaaS-badge
AMENDMENT NO. 1 dated as of March 14, 2003 to the U.S. Commercialization Agreement dated as of April 26, 2002 between Genta Incorporated ("Genta") and Aventis Pharmaceuticals Inc. ("Aventis") (as the same may be amended, supplemented or otherwise...
u.s. Commercialization Agreement • May 15th, 2003 • Genta Inc De/ • Biological products, (no disgnostic substances) • New York
Sample 1
Contract
u.s. Commercialization Agreement • April 30th, 2024 • Alvotech • Biological products, (no disgnostic substances)

Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals The high-concentration interchangeable biosimilar to Humira® manufactured by Alvotech will be distributed under Quallent’s private-label

Sample 1